Thelansis’s “Myasthenia Gravis (MG) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Myasthenia gravis is an autoimmune disorder in which the immune system produces antibodies that disrupt communication between nerves and muscles, causing fluctuating weakness that can affect the eyes, face, throat, limbs, and, in severe cases, breathing. For decades, treatment relied heavily on broad immune suppression through corticosteroids and related agents, which controlled symptoms but carried substantial long-term side effects. That has changed with two new classes of precision therapy targeting the specific immune mechanisms driving the disease rather than suppressing the immune system broadly, one blocking a receptor responsible for recycling harmful antibodies and the other interrupting a separate pathway that damages the nerve-muscle junction directly. Several agents within each class are now approved, giving physicians the ability to switch options when one is not well tolerated, and some therapies specifically address a less common antibody subtype that previously had fewer treatment options. These newer therapies are generally used alongside, rather than replacing, established immune-modulating treatment, with research now expanding toward B-cell targeted approaches.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*Survey is customized based on client requirements
1. Key Findings and Analyst Commentary
2. Competitive Landscape
3. Product Attribute Analysis
4. Primary Market Research
5. Unmet Need and TPP Analysis
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Myasthenia Gravis (MG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report
Our team will get in touch with you shortly about the Myasthenia Gravis (MG) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026 report.